Sub: Outcome of the Board Meeting held on November 9, 2023.
The Board of Directors of the Company at its meeting held today, November 9, 2023, has inter alia, transacted the following items of business:
Approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors.
Approved first interim dividend of 300% i.e., Rs.3.00 (Rupees three only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has already fixed November 20, 2023 as the record date for the purpose of payment of interim dividend for the financial year 2023-24 and the said interim dividend will be paid on or before December 4, 2023.
Based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the members through postal ballot, approved the appointment of Dr.Satakarni Makkapati (DIN. 09377266) as Non- executive and Non-independent Director of the Company with effect from November 9, 2023.
Approved purchase of entire equity shares of Theranym Biologics Private Limited, a step-down wholly owned subsidiary of the Company, from Curateq Biologics Private Limited, also a wholly owned subsidiary of the Company and make Theranym Biologics Private Limited a direct subsidiary of the Company.
The Board meeting commenced at 3.30 p.m. and concluded at 7.00 p.m.
Please take the information on record.
Yours faithfully,
For AUROBINDO PHARMA LIMITED
BADDIGAM ADI REDDY
Digitally signed by BADDIGAM ADI REDDY DN: c=IN, o=PERSONAL, title=7929, pseudonym=721d5e5f9caf4299ada369a8532fe7e6, 2.5.4.20=1249e67e239a72d275591952aaf4f0782b7b891 e8cac84dffa9adbec758f170d, postalCode=500008, st=Telangana, serialNumber=b1f6dfc33c7d7f200e2371074a7575404db e901e216efda16404f3ac51b96fca, cn=BADDIGAM ADI REDDY
Aurobindo Pharma Ltd. published this content on 09 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 November 2023 09:46:54 UTC.
Aurobindo Pharma specializes in the research, development, manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The group's activity is organized around 2 product families :
- generic drugs: for the treatment of neurological, cardiovascular, viral, gastroenterological, ophthalmologic and chronic diseases;
- active pharmaceutical ingredients.
At the end of March 2018, the group operated 23 production sites in India (19), the United States (3) and Brazil.
Net sales are distributed geographically as follows: India (12%), the United States (46.5%), Europe (31.2%) and other (10.3%).
AUROBINDO PHARMA 
